Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REPL 12.23.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-13
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur REPL Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.10.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.17.2025 - S-8 Securities to be offered to employees in employee benefit plans
  • 12.18.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

WOBURN, Mass.,Dec. 23, 2024(GLOBE NEWSWIRE) --Replimune Group, Inc.(Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of theReplimunemanagement team will present at the 43rdAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 13, 2025at2:15 PM PT.

A simultaneous webcast will be available in the Investors section of Replimune’s website atreplimune.com. A replay will be available for 30 days following the conference.

About ReplimuneReplimune Group, Inc., headquartered inWoburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visitreplimune.com.

Investor InquiriesChris BrinzeyICR Healthcare339.970.2843chris.brinzey@icrhealthcare.com

Media InquiriesArleen GoldenbergReplimune917.548.1582media@replimune.com

Replimune Group Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com